Wells Fargo Comments on Achillion (ACHN) After Patents Published

Wells Fargo maintained an Outperform rating on Achillion Pharmaceuticals (NASDAQ: ACHN). Comments follow news two patents were published that are believed to be related to its nuc, ACH-3422.

Analyst Brian Abrahams described the chemical structure as a deuterated cross between Gilead Sciences' (NASDAQ: GILD) sofosbuvir and Vertex Pharma's (NASDAQ: VRTX) discontinued nuc, VX135. Abrahams went on to say an early IP search suggests a possible path towards avoiding IP conflict.

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $10.89 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• Entergy Corp (ETR) PT Raised to $122 at Wells Fargo
• General Motors (GM) PT Raised to $30 at Wells Fargo